CD96 Is an Immune Checkpoint That Regulates CD8+ T-cell Antitumor Function
Deepak Mittal(QIMR Berghofer Medical Research Institute), Mark J. Smyth(Peter MacCallum Cancer Centre), Kimberley Stannard(QIMR Berghofer Medical Research Institute), Amelia Roman Aguilera(QIMR Berghofer Medical Research Institute), Ailin Lepletier(Griffith University), Stephen J. Blake(QIMR Berghofer Medical Research Institute), Jason Madore(QIMR Berghofer Medical Research Institute), Mark Bettington(The University of Queensland), Alan J. Korman(Bristol-Myers Squibb (Germany)), William C. Dougall(Queensland University of Technology), Georgina V. Long(The University of Sydney), Ruth Y. Lan(Bristol-Myers Squibb (Germany)), Kazuyoshi Takeda(National Center of Neurology and Psychiatry), Vicki Whitehall(The University of Queensland), Richard A. Scolyer(The University of Sydney), Robert J. Johnston(Johns Hopkins University), Nathan O. Siemers(Bristol-Myers Squibb (Germany)), Cheng Liu(Wenzhou Medical University), Michele W.L. Teng(The University of Queensland)
Cited by 117
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Nivolumab plus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2013|4.2k